相关实验视频
Updated: Jan 13, 2026
13:25
Acute Kidney Injury Model Induced by Cisplatin in Adult Zebrafish
Published on: May 15, 2021
6.5K
病中铜诱导的细胞死亡:分子机制和治疗含义
Daoyuan Lv1,2, Yafen Yu1,2
1Department of Nephrology, Affiliated Hospital of Jiangnan University, Wuxi, People's Republic of China.
Drug design, development and therapy
|January 7, 2026
概括
铜,细胞死途径由线粒体中过多的铜,是病的关键. 针对这种途径为脏疾病提供了新的诊断和治疗策略.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 细胞死亡途径 细胞死亡途径
- 线粒体生物学 线粒体生物学
背景情况:
- 铜体静止诱导cuproptosis,这是一个由线粒体铜过载驱动的新型调节细胞死亡途径.
- 脏的过和新陈代谢功能使其特别容易受到cuproptosis的影响.
- 杯性涉到FDX1介导的铜减少,脂化TCA酶聚合,铁硫蛋白不稳定,导致线粒体崩.
研究的目的:
- 审查cuproptosis在各种病理中的作用.
- 为了探索损伤中cuproptosis和ferroptosis之间的相互作用.
- 讨论新兴的诊断和治疗策略,以瘤学中囊亡为目标.
主要方法:
- 文献综述巩固了脏病理学中cuproptosis的证据.
- 分析 cuproptosis 背后的分子机制,包括 FDX1 调解和酶聚合.
- 检查cuproptosis和ferroptosis之间的协同相互作用.
主要成果:
- 质亡与急性损伤,糖尿病病和慢性病有关.
- 杯和铁之间的协同相互作用是由共同的途径介导的,例如谷氨酸枯竭和铁过载.
- 临床前研究表明,铜合剂,转运器调制剂和双抑制剂在减轻损伤方面具有前景.
结论:
- 向cuproptosis为脏病学的新诊断和治疗提供了一个有希望的途径.
- 需要进一步的研究来确定细胞类型特定的机制,并开发非侵入性生物标志物.
- 翻译应用和cuproptosis在修复中的作用需要未来的研究.
相关概念视频
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
256
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
256
01:25Chronic Kidney Disease I: Introduction
556
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
556
01:28Chronic Kidney Disease III: Interprofessional Care
333
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
333
01:29Acute Kidney Injury II: Pathophysiology
870
Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
870
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
205
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
205
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
915
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
915